Lipella Pharmaceuticals Inc. (LIPO)

USD 2.4

(6.19%)

Market Cap (In USD)

6.11 Million

Revenue (In USD)

449.61 Thousand

Net Income (In USD)

-4.61 Million

Avg. Volume

2.2 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.21-12.0
PE
-0.5
EPS
-4.79
Beta Value
1.4620692
ISIN
US53630L1008
CUSIP
53630L100
CIK
1347242
Shares
2548811.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jonathan Kaufman M.B.A., Ph.D.
Employee Count
-
Website
https://www.lipella.com
Ipo Date
2022-12-19
Details
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.